Nothing Special   »   [go: up one dir, main page]

CL2022001030A1 - Compuestos moduladores de glp-1r - Google Patents

Compuestos moduladores de glp-1r

Info

Publication number
CL2022001030A1
CL2022001030A1 CL2022001030A CL2022001030A CL2022001030A1 CL 2022001030 A1 CL2022001030 A1 CL 2022001030A1 CL 2022001030 A CL2022001030 A CL 2022001030A CL 2022001030 A CL2022001030 A CL 2022001030A CL 2022001030 A1 CL2022001030 A1 CL 2022001030A1
Authority
CL
Chile
Prior art keywords
glp
modulating compounds
compounds
agonists
kits
Prior art date
Application number
CL2022001030A
Other languages
English (en)
Inventor
Michael Graupe
Scott D Schroeder
Elbert Chin
Jeromy J Cottell
Zheng-Yu Yang
Chienhung Chou
James G Taylor
Nathan E Wright
Sheila M Zipfel
Stephen E Ammann
Gediminas J Brizgys
James S Cassidy
Chao-I Hung
Kavoos Kolahdouzan
Nathan D Shapiro
Daniel G Shore
Suzanne M Szewczyk
Rhiannon Thomas-Tran
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CL2022001030A1 publication Critical patent/CL2022001030A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente divulgación proporciona agonistas de GLP-1R y composiciones, métodos y kits de los mismos. Dichos compuestos son generalmente útiles para tratar una enfermedad o afección mediada por GLP-1R en un ser humano.
CL2022001030A 2019-10-25 2022-04-22 Compuestos moduladores de glp-1r CL2022001030A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926270P 2019-10-25 2019-10-25
US202063028187P 2020-05-21 2020-05-21

Publications (1)

Publication Number Publication Date
CL2022001030A1 true CL2022001030A1 (es) 2023-02-03

Family

ID=73449207

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001030A CL2022001030A1 (es) 2019-10-25 2022-04-22 Compuestos moduladores de glp-1r

Country Status (16)

Country Link
US (2) US11702404B2 (es)
EP (1) EP4048664A1 (es)
JP (2) JP7558267B2 (es)
KR (1) KR20220092909A (es)
CN (1) CN114630823A (es)
AU (2) AU2020369568B2 (es)
BR (1) BR112022007627A2 (es)
CA (1) CA3157525A1 (es)
CL (1) CL2022001030A1 (es)
CO (1) CO2022005077A2 (es)
CR (1) CR20220178A (es)
IL (1) IL292399A (es)
MX (1) MX2022004874A (es)
PE (1) PE20221040A1 (es)
TW (1) TWI790492B (es)
WO (1) WO2021081207A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4364798A3 (en) 2018-10-05 2024-06-19 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CA3136375A1 (en) * 2019-04-12 2020-10-15 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
KR20220092909A (ko) 2019-10-25 2022-07-04 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물
US20230002348A1 (en) * 2019-11-15 2023-01-05 Ildong Pharmaceutical Co., Ltd. GLP-1 Receptor Agonist and Use Thereof
KR20210059584A (ko) * 2019-11-15 2021-05-25 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
WO2021112538A1 (en) 2019-12-02 2021-06-10 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
EP4097097A1 (en) 2020-01-29 2022-12-07 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4097099B1 (en) 2020-02-07 2024-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TWI825398B (zh) * 2020-03-18 2023-12-11 南韓商Lg化學股份有限公司 Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法
KR102563111B1 (ko) * 2020-03-18 2023-08-04 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
AR123156A1 (es) * 2020-08-06 2022-11-02 Qilu Regor Therapeutics Inc Agonistas de glp-1r y sus usos
CA3190163A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN116406360A (zh) 2020-08-28 2023-07-07 加舒布鲁姆生物公司 杂环glp-1激动剂
MX2023003995A (es) 2020-10-05 2023-06-12 Enliven Inc Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl.
EP4227299A1 (en) * 2020-10-12 2023-08-16 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Benzimidazolone glp-1 receptor agonist and use thereof
CN116547279A (zh) * 2020-10-13 2023-08-04 加舒布鲁姆生物公司 杂环glp-1激动剂
CN114478497B (zh) * 2020-11-12 2023-10-20 杭州中美华东制药有限公司 芳基烷基酸类glp-1受体激动剂及其用途
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022111624A1 (zh) * 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CN114591308B (zh) * 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
US12091404B2 (en) 2021-03-11 2024-09-17 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するglp-1受容体作動薬を含有する医薬組成物
EP4303215A4 (en) * 2021-04-08 2024-09-18 Lg Chemical Ltd GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING IT AND PREPARATION METHOD THEREOF
WO2022225914A1 (en) * 2021-04-21 2022-10-27 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds
PE20240362A1 (es) * 2021-04-21 2024-03-04 Gilead Sciences Inc Compuestos moduladores del glp-ir carboxibenzimidazolicos
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CN117098758A (zh) 2021-06-24 2023-11-21 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
CN113480534B (zh) * 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
CA3227366A1 (en) * 2021-08-04 2023-02-09 Yidong Su Cycloalkene derivative regulator, preparation method therefor, and application thereof
JP2024532518A (ja) * 2021-08-30 2024-09-05 杭州徳睿智薬科技有限公司 Glp1rアゴニストとしての新規アリールエーテル置換複素環式化合物
JPWO2023038039A1 (es) 2021-09-08 2023-03-16
MX2024003872A (es) * 2021-09-27 2024-04-19 Terns Pharmaceuticals Inc Acidos carboxilicos de benzimidazol como agonistas de glp-1r.
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
EP4412707A1 (en) 2021-10-05 2024-08-14 Astrazeneca AB Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023138684A1 (en) * 2022-01-24 2023-07-27 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
IL315275A (en) * 2022-02-28 2024-10-01 Ascletis Bioscience Co Ltd GLP-1R modulatory compounds
WO2023169436A1 (zh) 2022-03-08 2023-09-14 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2023222084A1 (zh) * 2022-05-20 2023-11-23 成都地奥九泓制药厂 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用
WO2024028795A1 (en) * 2022-08-04 2024-02-08 Zydus Lifesciences Limited Heterobicyclic compounds as oral glp1r agonists
WO2024041609A1 (zh) * 2022-08-24 2024-02-29 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2024046342A1 (zh) * 2022-08-30 2024-03-07 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2024051749A1 (zh) * 2022-09-06 2024-03-14 德睿智药(苏州)新药研发有限公司 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
TW202432122A (zh) * 2022-12-13 2024-08-16 中國大陸商杭州中美華東製藥有限公司 Glp-1受體激動劑的新晶型和製備方法及其藥物組合物和用途
CN118496200A (zh) * 2023-02-14 2024-08-16 成都康弘药业集团股份有限公司 吲唑啉酮类化合物及其制备方法和用途
US20240360122A1 (en) * 2023-03-29 2024-10-31 Terns (Suzhou) Biotechnology Co., Ltd. Polymorphic forms and salts of a glp-1r agonist
WO2024206878A1 (en) * 2023-03-29 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
WO2024212742A1 (zh) * 2023-04-10 2024-10-17 上海研健新药研发有限公司 一种glp-1r激动剂,其制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2339018A1 (en) 1998-08-07 2000-02-17 Applied Research Systems Ars Holding N.V. Fsh mimetics for the treatment of infertility
EP1429759A4 (en) 2001-09-26 2004-12-15 Bristol Myers Squibb Co COMPOUNDS FOR TREATING HEPATITIS C VIRUS
MXPA05011539A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用
CA2588766A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
EP1838690A2 (en) 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
NZ566276A (en) 2005-09-16 2011-03-31 Arrow Therapeutics Ltd Biphenyl derivatives and their use in treating hepatitis C
BRPI0711040A2 (pt) 2006-03-31 2011-08-23 Astrazeneca Ab uso de um composto, método para o tratamento ou prevenção de distúrbios, composto, e, composição farmacêutica
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
CA2736970A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Pyrimidinone derivatives for use as medicaments
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
CN103153995B (zh) * 2010-06-24 2016-08-10 武田药品工业株式会社 作为磷酸二酯酶(pdes)抑制剂的稠合杂环化合物
BR112014003499A2 (pt) 2011-08-15 2017-06-13 Intermune Inc compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula
CN103059014B (zh) * 2011-10-21 2016-05-18 北京韩美药品有限公司 新型杂芳基氨基衍生物
CN104428293B (zh) 2012-06-11 2018-06-08 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类
WO2016018701A1 (en) * 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
KR20160066490A (ko) 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
MX2017009408A (es) 2015-01-20 2017-10-02 Merial Inc Compuestos antihelminticos, composiciones y metodo para usar los mismos.
US20170035881A1 (en) * 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
CA3015201C (en) * 2016-03-30 2023-07-04 Ishihara Sangyo Kaisha, Ltd. Pyridazinone compound or its salt, and herbicide containing it
BR112019012211A2 (pt) * 2016-12-16 2019-11-12 Pfizer agonistas de receptor de glp-1 e usos dos mesmos
CA3058182A1 (en) 2017-03-27 2018-10-04 Cardurion Pharmaceuticals, Llc Heterocyclic compound
US20200308165A1 (en) 2017-09-13 2020-10-01 D.E. Shaw Research, Llc Compounds as Ras Inhibitors and Use Thereof
MX2020008387A (es) 2018-05-08 2020-12-11 Vtv Therapeutics Llc Usos terapeuticos de agonistas glp1r.
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Glp-1受體促效劑及其用途
SG11202011704XA (en) 2018-06-15 2020-12-30 Pfizer Glp-1 receptor agonists and uses thereof
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
AU2019382642A1 (en) * 2018-11-22 2021-06-10 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CA3136375A1 (en) * 2019-04-12 2020-10-15 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CN112294760A (zh) 2019-07-26 2021-02-02 张晋宇 一种液体制剂及其应用
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
KR20220092909A (ko) 2019-10-25 2022-07-04 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물
KR20210053680A (ko) 2019-11-04 2021-05-12 주식회사 엘지화학 광변조 디바이스의 제조 방법
US20230002348A1 (en) 2019-11-15 2023-01-05 Ildong Pharmaceutical Co., Ltd. GLP-1 Receptor Agonist and Use Thereof
WO2021112538A1 (en) 2019-12-02 2021-06-10 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
EP4097097A1 (en) 2020-01-29 2022-12-07 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4097099B1 (en) 2020-02-07 2024-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20230165846A1 (en) 2020-02-13 2023-06-01 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TWI825398B (zh) 2020-03-18 2023-12-11 南韓商Lg化學股份有限公司 Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法
JP2021155415A (ja) 2020-03-27 2021-10-07 ファイザー・インク 2−[(4−{6−[(4−シアノ−2−フルオロベンジル)オキシ]ピリジン−2−イル}ピペリジン−1−イル)メチル]−1−[(2s)−オキセタン−2−イルメチル]−1h−ベンゾイミダゾール−6−カルボン酸またはその薬学的な塩を用いた2型糖尿病、または肥満、または過体重の治療
CN113493447B (zh) 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN115867546B (zh) 2020-05-27 2024-10-18 上海齐鲁锐格医药研发有限公司 Glp-1r激动剂的盐和晶形及其用途
AU2021286086B2 (en) 2020-06-04 2023-09-07 Hangzhou Sciwind Biosciences Co., Ltd Five-membered heteroaromatic imidazole compound and use thereof
CN113816948B (zh) 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
AR123156A1 (es) * 2020-08-06 2022-11-02 Qilu Regor Therapeutics Inc Agonistas de glp-1r y sus usos
IL300795A (en) 2020-08-21 2023-04-01 Terns Pharmaceuticals Inc Compounds as GLP-1R agonists
CN115515956B (zh) 2020-09-29 2024-06-25 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
EP4227299A1 (en) 2020-10-12 2023-08-16 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Benzimidazolone glp-1 receptor agonist and use thereof
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022111624A1 (zh) 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
US12091404B2 (en) 2021-03-11 2024-09-17 Gilead Sciences, Inc. GLP-1R modulating compounds
EP4304712A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
JP2024514259A (ja) * 2021-04-08 2024-03-29 エルジー・ケム・リミテッド Glp-1受容体作動薬、それを含む薬学的組成物、およびその製造方法
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用

Also Published As

Publication number Publication date
CN114630823A (zh) 2022-06-14
CO2022005077A2 (es) 2022-05-10
MX2022004874A (es) 2022-05-13
BR112022007627A2 (pt) 2022-07-12
EP4048664A1 (en) 2022-08-31
AU2024203850A1 (en) 2024-06-27
US11702404B2 (en) 2023-07-18
KR20220092909A (ko) 2022-07-04
AU2020369568B2 (en) 2024-03-21
CA3157525A1 (en) 2021-04-29
TW202130630A (zh) 2021-08-16
WO2021081207A1 (en) 2021-04-29
US20230391747A1 (en) 2023-12-07
CR20220178A (es) 2022-06-15
PE20221040A1 (es) 2022-06-17
AU2020369568A1 (en) 2022-05-05
TW202317535A (zh) 2023-05-01
JP7558267B2 (ja) 2024-09-30
JP2023184759A (ja) 2023-12-28
TWI790492B (zh) 2023-01-21
US20210171499A1 (en) 2021-06-10
JP2022552735A (ja) 2022-12-19
IL292399A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
CL2022001030A1 (es) Compuestos moduladores de glp-1r
CO2023013766A2 (es) Compuestos carboxi-benzimidazol moduladores de glp-1r
CL2023003119A1 (es) Compuestos moduladores del glp-ir carboxibenzimidazólicos
CO2021005884A2 (es) Moduladores de la alfa-1 antitripsina
CO2019007829A2 (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
ECSP21026021A (es) Moduladores de la expresión de pnpla3
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
ECSP21053104A (es) Moduladores de la expresión de hsd17b13
ECSP19072372A (es) Moduladores de la expresión de pcsk9
ECSP20082339A (es) Moduladores de la expresión de apol1
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
CL2021001246A1 (es) Moduladores de expresión irf5.
UY38352A (es) Inhibidores de integrina alfavbeta6
UY38472A (es) Moduladores de la expresión de foxp3
PE20200749A1 (es) Moduladores de la expresion de enac
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
AR117079A1 (es) Moduladores de la expresión de foxp3
EA202191657A1 (ru) Модуляторы экспрессии hsd17b13
AR117593A1 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias